A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS). These studies have been performed mostly on a small scale and on whole blood mononuclear cells (PBMC). In a number of cases, RRMS progresses to a severe secondary neurodegenerative form. In this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.
SEP-MIR is a prospective, single-center, descriptive study. Participants will be recruited among adult patients with RRMS coming for a follow-up consultation in the Neurology Department, Nervous System Diseases Pole, at the hôpital Pitié - Salpêtrière (Paris). As this is a descriptive study, the recruitment of 20 participants (10 patients with relapsing-remitting MS and 10 patients with relapsing-remitting MS) should meet the objectives of this study. A 50 ml blood sample will be obtained from each participant and several clinical data regarding their pathology will be collected.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
20
50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
Hôpital La Pitié - Salpêtrière
Paris, France
microRNA expression profiles in immune cell populations from RRMS patients
RNAseq and/or Nanostring sequencing of PBMCs from RRMS patients
Time frame: 2 years
microRNA expression profiles in unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients
RNAseq and/or Nanostring sequencing of unstimulated and stimulated CD4+ T cell populations ex vivo from RRMS patients
Time frame: 2 years
microRNA expression profiles in monocytes from RRMS patients
RNAseq and/or Nanostring sequencing of monocytes from RRMS patients
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.